Eligard
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metastatic Prostate Cancer
Conditions
Metastatic Prostate Cancer
Trial Timeline
Aug 1, 2014 → Aug 1, 2015
NCT ID
NCT01933022About Eligard
Eligard is a approved stage product being developed by Astellas Pharma for Metastatic Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01933022. Target conditions include Metastatic Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Prostate Cancer were approved
Approved (20) Terminated (7) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02274779 | Phase 2 | Completed |
| NCT01933022 | Approved | Terminated |
Competing Products
20 competing products in Metastatic Prostate Cancer